On June 8, CSPC Pharmaceutical Group fell 3.18% in regular trading, trading at HKD 7.09/share, with trading volume of HKD 93.16 million. The decline reflects continued pressure from multiple headwinds including sector-wide weakness, management instability, and subdued earnings recovery.
On the news front, the pharmaceutical sector extended its broad-based weakness, with peers posting widespread declines. More notably, the company has experienced a wave of senior management departures in recent months. Executive Director Wang Huaiyu formally resigned due to retirement on June 5, following earlier exits by former Global R&D President Liu Yongjun, former CEO Zhang Cuilong, and former Chief Medical Officer Hei Yongjiang, raising market concerns over leadership stability amid the transition to second-generation management under new CEO Cai Lei.
Fundamentally, BOCOM International recently cut its target price to HKD 8.05, maintaining a neutral rating, citing uncertainty in core business recovery. Q1 attributable net profit fell 41.8% year-over-year, and even after stripping out the high licensing fee base, core profit still declined 7.3%, suggesting sluggish momentum in the main pharmaceutical business.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments